Recent Security Class Actions

Humacyte Inc. Common Stock (NASDAQ: HUMA)

37 Days left to seek lead plaintiff status.

Company Name:Humacyte Inc. Common Stock
Stock Symbol:NASDAQ: HUMA
Class Period Start:05/10/2024
Class Period End (inclusive):10/17/2024
Filing Deadline:01/17/2025

The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, the Complaint alleges Defendants failed to disclose to investors: (1) that the Company’s Durham, North Carolina facility failed to comply with good manufacturing practices, including quality assurance and microbial testing; (2) that the FDA’s review of the BLA would be delayed while Humacyte remediated these deficiencies; and (3) that, as a result, there was a substantial risk to FDA approval of ATEV for vascular trauma; and (4) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Humacyte Inc. Common Stock (NASDAQ: HUMA) Claim Form

Name(Required)
Address
This field is for validation purposes and should be left unchanged.